The new platform broadens Cellenion’s single cell dispensing solutions portfolio by enabling the isolation and handling of cellular aggregates from 80 µm to 600 µm including spheroids, organoids, and tumoroids
Today, SCIENION & Cellenion, BICO companies, announced the launch of spheroONE, an innovative single large-particle sorter and dispenser which will revolutionize 3D cellular model handling. The platform is capable of dispensing individual spheroids, organoids, and tumoroids and complements Cellenion’s hugely successful cellenONE® platform for single cell isolation. The launch advances BICO’s Bio Convergence agenda by enabling easier use of complex in vitro 3D models that are more physiologically relevant, predictive and have the potential to complement and in some cases replace animal models in drug screening and other applications like cancer research.
“Current offerings suffer from low throughput, inconsistent sorting, and intensive manual dispensing,” explained Guilhem Tourniaire, PhD, Managing Director & Founder at Cellenion. “spheroONE is going to play a significant role toward replacing animal models in pre-clinical research as it allows automated sorting, enables development of higher quality and yield models, and improves outcome of 3D cell assays.”
spheroONE combines SCIENION’s sciDROP NANO precision dispensing technology with advanced image-based capabilities to enable precision isolation, sorting, and dispensing of single spheroids, organoids and tumoroids. The platform uses electromagnetic microvalve technology for gentle drop-on-demand generation in air which ensures maintenance of the integrity and viability of fragile cellular aggregates. Its combination of image-based capabilities, sorting and dispensing makes it the perfect platform for improving reproducibility of 3D model-based drug screens.
Other key features of spheroONE include:
- Up to 100% accurate automated isolation of single cellular aggregates using morphology and fluorescence-based sorting
- Controlled biomass via user-defined parameters (size and number of spheroids per well), facilitating high quality toxicological assays
- Streamlined drug screening on spheroids grown in bulk, reducing labor and enabling standardized 3D model-based assays
The spheroONE will broaden Cellenion’s customers’ ability to conduct vital life sciences research by enabling the handling of cellular aggregates ranging from 80 µm to 600 µm. The company’s cellenONE is already a reference in sorting and dispensing any cells from 0.5 – 80 µm with applications in single cell genomics, transcriptomics, proteomics, cell line development and rare cells.
Companies and organizations interested in the spheroONE can find more information at: www.cellenion.com/products/spheroone/
BICO Press office
Riley Munks, PR Manager (650) 863-6699
Alyssa D’Orazio, PR Manager (617) 634-960
Founded in 2001, SCIENION is a renowned specialist in ultra-low volume precision liquid handling in the pico-liter to micro-liter range, enabling applications from research to high-throughput production of assays in diagnostics and life sciences. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION is a complete solution provider offering a unique portfolio of automated precision dispensing systems, readers, consumables, assay development and contract manufacturing services. The company operates from two sites in Germany, Dortmund and Berlin, and has subsidiaries in Arizona, USA; Chichester, UK; and Cellenion in Lyon, France.
SCIENION is part of BICO, the leading bio convergence company in the world that provides technologies, products and services to create the future of health.
Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of single cell and single cellular aggregates isolation. Our systems allow high throughput, image-based automated dispensing of single cells and/or cell aggregates onto any substrates of choice. Together with a range of dedicated consumables, the solutions enable miniaturization of sample preparation protocols on the same instrument before downstream analysis. With no dead volumes and outstanding recovery rates, Cellenion’s platforms offer unique capacities for applications including single-cell omics, rare cells, cell line development, drug screening and 3D model development. Cellenion operates from Lyon, France. The company is a subsidiary of SCIENION GmbH and its products are sold by SCIENION worldwide.
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people’s health and lives for the better.
With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,000 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com